Question 1

What is the difference between Tecentriq and Opdivo?

Accepted Answer

Tecentriq is Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system. and is developed by Roche. Opdivo is Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells. and is developed by Bristol-Myers Squibb.

Question 2

What are Tecentriq and Opdivo used for?

Accepted Answer

Tecentriq: Extensive stage primary small cell carcinoma of lung, Germline BRCA-mutated, HER2-negative metastatic breast cancer, Liver cell carcinoma. Opdivo: Advanced melanoma with tumour cell PD-L1 expression below 1%, Classical Hodgkin lymphoma, Head and neck cancer.

Question 3

Are Tecentriq and Opdivo in the same drug class?

Accepted Answer

Yes — both are Programmed Death Receptor-1 Blocking Antibody [EPC].

	Tecentriq	Opdivo
Generic name	atezolizumab	nivolumab
Sponsor	Roche	Bristol-Myers Squibb
Drug class	Programmed Death Receptor-1 Blocking Antibody [EPC]	Programmed Death Receptor-1 Blocking Antibody [EPC]
Molecular target	Programmed cell death 1 ligand 1	Programmed cell death protein 1
Modality	Monoclonal antibody	Monoclonal antibody
Phase	FDA-approved	FDA-approved
Therapeutic area	Oncology	Oncology
First approval	2016	2014

Tecentriq vs Opdivo

At a glance

Mechanism of action

Approved indications

Tecentriq

Opdivo

Common side effects

Tecentriq

Opdivo

Further reading

Tecentriq	Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system.
Opdivo	Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells.